PENTAXIM

This brand name is authorized in Brazil, Cyprus, Estonia, Hong Kong, Croatia, Lithuania, Poland, Singapore, Tunisia, Turkey, South Africa

Active ingredients

The drug PENTAXIM contains a combination of these active pharmaceutical ingredients (APIs):

1 Tetanus toxoid UNII K3W1N8YP13 - CLOSTRIDIUM TETANI TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED)

Read about Tetanus toxoid

2 Diphtheria toxoid UNII IRH51QN26H - CORYNEBACTERIUM DIPHTHERIAE TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED)

Read about Diphtheria toxoid

3 Pertussis toxoid UNII F4TN0IPY37 - BORDETELLA PERTUSSIS TOXOID ANTIGEN (GLUTARALDEHYDE INACTIVATED)

Read about Pertussis toxoid

4 Pertussis filamentous hemagglutinin UNII 8C367IY4EY - BORDETELLA PERTUSSIS FILAMENTOUS HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED)

Read about Pertussis filamentous hemagglutinin

5 Mahoney strain UNII 0LVY784C09 - POLIOVIRUS TYPE 1 ANTIGEN (FORMALDEHYDE INACTIVATED)

Read about Poliomyelitis, serotype 1

6 MEF-1 strain UNII 23JE9KDF4R - POLIOVIRUS TYPE 2 ANTIGEN (FORMALDEHYDE INACTIVATED)

Read about Poliomyelitis, serotype 2

7 Saukett strain UNII 459ROM8M9M - POLIOVIRUS TYPE 3 ANTIGEN (FORMALDEHYDE INACTIVATED)

Read about Poliomyelitis, serotype 3

8 Polysaccharide of Haemophilus influenzae type b UNII LUY6P8763W - HAEMOPHILUS INFLUENZAE TYPE B CAPSULAR POLYSACCHARIDE MENINGOCOCCAL OUTER MEMBRANE PROTEIN CONJUGATE ANTIGEN

Read about

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
PENTAXIM Powder and suspension for suspension for injection	Υπουργείο Υγείας (CY)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J07CA06	Diphtheria-Haemophilus influenzae B-pertussis-poliomyelitis-tetanus	J Antiinfectives for systemic use → J07 Vaccines → J07C Bacterial and viral vaccines, combined → J07CA Bacterial and viral vaccines, combined
Discover more medicines within J07CA06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 502820050079907, 502820050080007, 576720060074417, 576720060074517, 576720090087107, 576720090087207
Country: EE	Ravimiamet	Identifier(s): 1135033, 1135044, 1135055
Country: HK	Department of Health Drug Office	Identifier(s): 56018
Country: HR	Agencija za lijekove i medicinske proizvode	Identifier(s): HR-H-854134391
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1012679, 1068299, 1068300, 1068301, 1068512, 1068513
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100192717
Country: SG	Health Sciences Authority	Identifier(s): 14795P
Country: TN	Direction de la Pharmacie et du Médicament	Identifier(s): 12063051
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699625960336
Country: ZA	Health Products Regulatory Authority	Identifier(s): A38/30.1/0525